FibroBiologics CEO Issues Letter to Shareholders

FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and ...
Pharmabiz

FibroBiologics submits IND application with US FDA to initiate clinical trials of CYPS317 in psoriasis patients

FibroBiologics submits IND application with US FDA to initiate clinical trials of CYPS317 in psoriasis patients: Houston Saturday, January 3, 2026, 11:00 Hrs [IST] FibroBiologics ...
Labmate Online

Sugars found in food cut alcohol drinking in mice by acting on appetite signals

Researchers at Kyoto University have reported that rare sugars which induce fibroblast growth factor 21 signalling reduced ...

FibroBiologics Announces Positive Preclinical Results for a Fibroblast Spheroid-derived Chondrocyte (FSdC) Spheroid Therapy for Degenerative Disc Disease

FibroBiologics is pursuing a development program for FSdC spheroids with the goal of advancing to clinical trials. The data includes comprehensive preclinical pharmacology and efficacy assessments ...
TipRanks on MSN

FibroBiologics announces preclinical results for FSDC

FibroBiologics (FBLG) announced preclinical results for FSdC, an investigational FSdC spheroid-based therapy, demonstrating superior improvement ...

FibroBiologics Files IND Application with the U.S. FDA to Advance Clinical Development of CYPS317 in Patients with Psoriasis

FibroBiologics is pursuing a development program for CYPS317 with the goal of advancing first-in-human clinical trials following FDA review of the IND filing. The IND submission includes comprehensive ...
eLife

Opioid Use Disorder: Identifying new targets in the fight against opioids

Experiments reveal that a time-dependent epistatic interaction influences how mice respond to opioids, and that intracellular fibroblast growth factors also influence opioid sensitivity.